| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Helen I. Torley
Also a director
PRESIDENT AND CEO
Title from the Form 4 dated Oct 6, 2026
|
63 | Not stated | Not stated | $23,166,223 | |
|
Nicole LaBrosse
SVP, CHIEF FINANCIAL OFFICER
Title from the Form 4 dated Feb 20, 2026
|
Not stated | Not stated | Not stated | $4,578,814 | |
|
Darren Snellgrove
SVP, Chief Financial Officer
Title from the Form 4 dated Jul 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Mark Snyder
SVP, CHIEF LEGAL OFFICER
Title from the Form 4 dated Jun 12, 2026
|
Not stated | Not stated | Not stated | $4,531,568 | |
|
David A Ramsay
EVP, PRESIDENT, DRUG DELIVERY
Title from the Form 4 dated Jun 30, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Mar 23, 2026 · updated by the 8-Ks of Aug 18, 2026 and Sep 30, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Jeffrey W. Henderson
Board chair
|
61 |
2015
11 years
|
Independent |
Audit Committee
|
Becton Dickinson and Company, a medical technology company | $540,039 | |
|
Helen I. Torley
CEO
|
63 |
2014
12 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Bernadette Connaughton
|
67 |
2018
8 years
|
Independent | None stated | Editas Medicine, Inc., a clinical stage biotechnology company | $470,039 | |
|
Matthew L. Posard
|
58 |
2013
13 years
|
Independent | None stated | Nautilus Biotechnology, Inc., (Chairman) a development stage life sciences company | $475,039 | |
|
Barbara Duncan
|
61 |
2023
3 years
|
Independent |
Audit Committee · Chair
Compensation Committee
|
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company | $490,039 | |
|
Mahesh Krishnan
|
55 |
2024
2 years
|
Independent |
Nominating and Corporate Governance Committee
Compensation Committee
|
None stated | $461,715 | |
|
James Lang
|
61 |
2025
1 year
|
Independent | None stated | BioVie, Inc., a clinical stage biopharmaceutical company | $3,668 | |
|
Dannielle Appelhans
Joined Aug 14, 2026
|
- | - | - | - | - | - | |
|
James Daly
Joined Sep 28, 2026
|
- | - | - | - | - | - | |
|
Moni Miyashita
Leaving at the meeting
|
Not stated | Not stated | Independent |
Nominating and Corporate Governance Committee
|
None stated | $455,039 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Mar 23, 2026 states there were none.
Read it in the proxyLoading...
